rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Novavax, Inc.

NVAX · Nasdaq

Health CareBiotechnologyIn trend

NVAX stood above a rising 150-day average in 31 of the last 52 weekly readings, including each of the last 9 weeks. It is 22.1% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
In trend
Weeks in an uptrend
9 in a row
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
2
Institutions holding
253 (+9)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 31 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$115K$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

2 disclosed lines: House 0, Senate 2, executive 0; 1 people.

WhoDidAmountTraded
Pat Roberts Senate: U.S. Senate eFDSenatorsoldspouse$1k–$15k13 Oct 2020filed 5 Nov 2020
Pat Roberts Senate: U.S. Senate eFDSenatorboughtspouse$1k–$15k17 Aug 2020filed 30 Aug 2020

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders253+9 on the quarter
New · exited43 · 34
Reported value$1.1B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
SHAH CAPITAL MANAGEMENTreduced · filed 14 Aug 202614,165,577$133.4M-679,520−4.6%
BlackRock, Inc.added · filed 7 Aug 202613,946,881$131.4M+1,102,562+8.6%
STATE STREET CORPadded · filed 7 Aug 202611,740,550$110.6M+2,770,032+30.9%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 20267,607,996$71.7M+456,371+6.4%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20267,257,449$68.4M+127,302+1.8%
Sanofiunchanged · filed 28 Jul 20266,880,481$64.8M00.0%
D. E. Shaw & Co., Inc.reduced · filed 14 Aug 20265,650,905$53.2M-2,058,953−26.7%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20264,207,370$39.6M+308,957+7.9%
TWO SIGMA INVESTMENTS, LPadded · filed 14 Aug 20264,091,043$38.5M+3,476,244+565.4%
COATUE MANAGEMENT LLCunchanged · filed 14 Aug 20263,836,986$36.1M00.0%
31 Mar 2023 – 30 Jun 2026
177214250Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

David M. Mott Company insiderDirector · last 20 Jun 20260 · 1
Gregg H. Alton Company insiderDirector · last 20 Jun 20260 · 0
Margaret G. McGlynn Company insiderDirector · last 20 Jun 20260 · 0
Rachel K. King Company insiderDirector · last 20 Jun 20262 · 1
Richard Douglas Company insiderDirector · last 20 Jun 20267 · 0
Richard J. Rodgers Company insiderDirector · last 20 Jun 20260 · 0
Charles W. Newton Company insiderDirector · last 18 Jun 20260 · 0
John W. Shiver Company insiderDirector · last 18 Jun 20260 · 0
Robert Edward Walker Company insiderEVP, R&D · last 14 Apr 20260 · 0
James Patrick Kelly Company insiderEVP, CFO and Treasurer · last 7 Mar 20260 · 0
Elaine O'Hara Company insiderEVP, Chief Strategy Officer · last 3 Mar 20260 · 0
John C. Jacobs Company insiderPresident and CEO · last 3 Mar 20260 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

Awards1
Total$121.4M
Latest24 Feb 2011

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202593.5%
Operating profit marginFY 2025 · to 31 Dec 202540.3%
Return on capital employedFY 2025 · to 31 Dec 202563.2%
Cash conversionFY 2025 · to 31 Dec 2025-55.6%
Interest coverFY 2025 · to 31 Dec 202539.28×
Research spendFY 2025 · to 31 Dec 202530.5%
Share count trendFY 2025 · to 16 Feb 20260.2%
Cash and equivalentsFY 2025 · to 31 Dec 2025$240.6M

Analyst forecasts

No analyst forecasts yet.